United Therapeutics Corporation $UTHR Shares Bought by Ethic Inc.

Ethic Inc. raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 13.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 901 shares of the biotechnology company’s stock after acquiring an additional 104 shares during the period. Ethic Inc.’s holdings in United Therapeutics were worth $256,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. HB Wealth Management LLC raised its holdings in United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 35 shares during the last quarter. Hohimer Wealth Management LLC raised its holdings in United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock valued at $3,900,000 after acquiring an additional 37 shares during the last quarter. Park Avenue Securities LLC raised its holdings in United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 39 shares during the last quarter. Applied Finance Capital Management LLC raised its holdings in United Therapeutics by 3.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 40 shares during the last quarter. Finally, Headlands Technologies LLC raised its holdings in United Therapeutics by 1.5% in the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock valued at $828,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $453.53 on Friday. The stock has a market capitalization of $20.46 billion, a P/E ratio of 17.19, a PEG ratio of 4.96 and a beta of 0.66. The company has a 50 day moving average price of $407.40 and a 200 day moving average price of $336.86. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $479.50.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the company posted $6.39 EPS. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 364,435 shares of company stock valued at $151,067,172 in the last ninety days. 10.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on UTHR. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Wednesday. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, Bank of America increased their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $483.73.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.